Regeneron Pharmaceuticals
REGN
1,318 hedge funds and large institutions have $66.7B invested in Regeneron Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 169 funds opening new positions, 480 increasing their positions, 493 reducing their positions, and 213 closing their positions.
2% more call options, than puts
Call options by funds: $1.19B | Put options by funds: $1.17B
0.03% less ownership
Funds ownership: 86.56% → 86.53% (-0.03%)
3% less repeat investments, than reductions
Existing positions increased: 480 | Existing positions reduced: 493
5% less funds holding
Funds holding: 1,389 → 1,318 (-71)
21% less first-time investments, than exits
New positions opened: 169 | Existing positions closed: 213
32% less capital invested
Capital invested by funds: $97.5B → $66.7B (-$30.8B)
39% less funds holding in top 10
Funds holding in top 10: 23 → 14 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
+$1.17B |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$680M |
| 3 |
Amundi
Paris,
France
|
+$409M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$331M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$243M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.82B |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$1.28B |
| 3 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$739M |
| 4 |
Capital Research Global Investors
Los Angeles,
California
|
-$678M |
| 5 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$419M |
REGN Hedge Fund Activity: Q4 2024 in Review
1,318 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Regeneron Pharmaceuticals (REGN) for Q4 2024, worth a combined $66.7B — down 32% from $97.5B a quarter earlier.
Sellers outnumbered buyers: 213 funds closed out of REGN and 169 opened new positions — a net loss of 44 holders — while 493 trimmed existing stakes and 480 added.
The largest buyer was Capital International Investors, adding an estimated $1.17B. The largest seller was Fidelity Investments, cutting an estimated $1.82B.
- 1,318 institutional investors held Regeneron Pharmaceuticals (REGN) as of Q4 2024, down from 1,389 in Q3 2024.
- Funds reported $66.7B of Regeneron Pharmaceuticals stock for Q4 2024, down 32% quarter-over-quarter.
- 169 funds opened new Regeneron Pharmaceuticals positions in Q4 2024 and 213 closed out, a net change of -44 holders.
- The largest Regeneron Pharmaceuticals buyer in Q4 2024 was Capital International Investors, an estimated $1.17B added.
- The largest Regeneron Pharmaceuticals seller in Q4 2024 was Fidelity Investments, an estimated $1.82B sold.
Based on aggregated 13F filings for Q4 2024.